Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2020

01-12-2020 | Hyperthyroidism | Research article

Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves’ disease patients

Authors: Rui-Ting Hu, De-Shan Liu, Bin Li

Published in: BMC Endocrine Disorders | Issue 1/2020

Login to get access

Abstract

Background

Radioactive iodine (RAI) therapy is an important treatment option for Graves’ disease (GD), the main side effect of RAI treatment is hypothyroidism, and the factors resulting in hypothyroidism are still controversial. The purpose of this retrospective study was to clarify the possible risk factors of early hypothyroidism after RAI therapy in Graves’ disease.

Methods

We reviewed 312 GD patients treated with RAI between January 2017 to December 2018, collected the potential risk factors, and analyzed the relationship between these variables and early hypothyroidism.

Results

After 6 months’ follow-up, 218 (69.87%) patients were evaluated as early hypothyroid. Male gender, shorter duration of disease, smaller thyroid weight, lower 2-h radioactive iodine uptake (RAIU), 6-h RAIU, 24-h RAIU and 6/24-h uptake ratio, lower administered dosages were significantly associated with early hypothyroidism. Logistics regression analysis showed that male gender, smaller thyroid weight and lower 6-h RAIU were associated with early hypothyroidism. Multi-factors combined ROC curve analysis suggested that the predictive power of male gender, smaller thyroid weight and lower 6-h RAIU for early hypothyroidism was 0.711.

Conclusions

Our results show that RAI is an effective therapy for GD and most of the cured patients became to hypothyroid within 6 months. Male gender, smaller thyroid weight and lower 6-h RAIU are the main risk factors for early hypothyroidism.
Literature
1.
go back to reference Smith TJ, Longo DL, Hegedüs L. Graves’ disease. N Engl J Med. 2016;375(16):1552–65.PubMed Smith TJ, Longo DL, Hegedüs L. Graves’ disease. N Engl J Med. 2016;375(16):1552–65.PubMed
2.
go back to reference Hussain YS, Hookham JC, Allahabadia A, Balasubramanian SP. Epidemiology, management and outcomes of graves’ disease—real life data. Endocrine. 2017;56(3):568–78.PubMedPubMedCentral Hussain YS, Hookham JC, Allahabadia A, Balasubramanian SP. Epidemiology, management and outcomes of graves’ disease—real life data. Endocrine. 2017;56(3):568–78.PubMedPubMedCentral
3.
go back to reference Azizi F, Malboosbaf R. Long-term Antithyroid drug treatment: a systematic review and meta-analysis. Thyroid. 2017;27(10):1223–31.PubMed Azizi F, Malboosbaf R. Long-term Antithyroid drug treatment: a systematic review and meta-analysis. Thyroid. 2017;27(10):1223–31.PubMed
4.
go back to reference Wiersinga WM. Graves' disease: can it be cured? Endocrinol Metab. 2019;34(1):29. Wiersinga WM. Graves' disease: can it be cured? Endocrinol Metab. 2019;34(1):29.
5.
go back to reference Sjölin G, Holmberg M, Törring O, Byström K, Khamisi S, de Laval D, Abraham-Nordling M, Calissendorff J, Lantz M, Hallengren B, et al. The long-term outcome of treatment for Graves' hyperthyroidism. Thyroid. 2019;29(11):1545–57.PubMed Sjölin G, Holmberg M, Törring O, Byström K, Khamisi S, de Laval D, Abraham-Nordling M, Calissendorff J, Lantz M, Hallengren B, et al. The long-term outcome of treatment for Graves' hyperthyroidism. Thyroid. 2019;29(11):1545–57.PubMed
6.
go back to reference Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet. 2012;379(9821):1155–66.PubMed Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet. 2012;379(9821):1155–66.PubMed
7.
go back to reference Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS. Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013;98(9):3671–7.PubMedPubMedCentral Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS. Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013;98(9):3671–7.PubMedPubMedCentral
8.
go back to reference Masiello E, Veronesi G, Gallo D, Premoli P, Bianconi E, Rosetti S, Cusini C, Sabatino J, Ippolito S, Piantanida E, et al. Antithyroid drug treatment for graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Investig. 2018;41(12):1425–32. Masiello E, Veronesi G, Gallo D, Premoli P, Bianconi E, Rosetti S, Cusini C, Sabatino J, Ippolito S, Piantanida E, et al. Antithyroid drug treatment for graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Investig. 2018;41(12):1425–32.
9.
go back to reference Sundaresh V, Brito JP, Thapa P, Bahn RS, Stan MN. Comparative effectiveness of treatment choices for Graves' hyperthyroidism: a historical cohort study. Thyroid. 2017;27(4):497–505.PubMedPubMedCentral Sundaresh V, Brito JP, Thapa P, Bahn RS, Stan MN. Comparative effectiveness of treatment choices for Graves' hyperthyroidism: a historical cohort study. Thyroid. 2017;27(4):497–505.PubMedPubMedCentral
10.
go back to reference Aung ET, Zammitt NN, Dover AR, Strachan MWJ, Seckl JR, Gibb FW. Predicting outcomes and complications following radioiodine therapy in graves’ thyrotoxicosis. Clin Endocrinol. 2019;90(1):192–9. Aung ET, Zammitt NN, Dover AR, Strachan MWJ, Seckl JR, Gibb FW. Predicting outcomes and complications following radioiodine therapy in graves’ thyrotoxicosis. Clin Endocrinol. 2019;90(1):192–9.
11.
go back to reference Li J, Zhang L, Zhang Z, Liu J, Zhang H, Lin X, Jiang N. Factors suggesting relapse of Grave's disease after first radioiodine therapy. Analysis of 607 cases. Hell J Nucl Med. 2019;22(1):64–9.PubMed Li J, Zhang L, Zhang Z, Liu J, Zhang H, Lin X, Jiang N. Factors suggesting relapse of Grave's disease after first radioiodine therapy. Analysis of 607 cases. Hell J Nucl Med. 2019;22(1):64–9.PubMed
12.
go back to reference Xing YZ, Zhang K, Jin G. Predictive factors for the outcomes of Graves’ disease patients with radioactive iodine (131I) treatment. Biosci Rep. 2019;40(1). Xing YZ, Zhang K, Jin G. Predictive factors for the outcomes of Graves’ disease patients with radioactive iodine (131I) treatment. Biosci Rep. 2019;40(1).
13.
go back to reference de Jong JA, Verkooijen HM, Valk GD, Zelissen PM, de Keizer B. High failure rates after (131) I therapy in graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover. Clin Nucl Med. 2013;38(6):401–6.PubMed de Jong JA, Verkooijen HM, Valk GD, Zelissen PM, de Keizer B. High failure rates after (131) I therapy in graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover. Clin Nucl Med. 2013;38(6):401–6.PubMed
14.
go back to reference Zheng W, Jian T, Guizhi Z, Zhaowei M, Renfei W. Analysis of 131i therapy and correlation factors of graves’disease patients. Nucl Med Commun. 2012;33(1):97–101.PubMed Zheng W, Jian T, Guizhi Z, Zhaowei M, Renfei W. Analysis of 131i therapy and correlation factors of graves’disease patients. Nucl Med Commun. 2012;33(1):97–101.PubMed
15.
go back to reference Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab. 2003;88(3):978–83.PubMed Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab. 2003;88(3):978–83.PubMed
16.
go back to reference Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, et al. 2016 American Thyroid Association guidelines for diagnosis and Management of Hyperthyroidism and Other Causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–421.PubMed Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, et al. 2016 American Thyroid Association guidelines for diagnosis and Management of Hyperthyroidism and Other Causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–421.PubMed
17.
go back to reference Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab. 2012;97(12):4549–58.PubMed Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab. 2012;97(12):4549–58.PubMed
18.
go back to reference Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves' disease. Clin Endocrinol. 2016;84(1):115–20. Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves' disease. Clin Endocrinol. 2016;84(1):115–20.
19.
go back to reference Seib CD, Chen J, Iagaru A. Shifting trends and informed decision making in the Management of Graves' disease. Thyroid. 2020. Seib CD, Chen J, Iagaru A. Shifting trends and informed decision making in the Management of Graves' disease. Thyroid. 2020.
20.
go back to reference Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, Latrofa F, Mammoli C, Lippi F, Ceccarelli C, et al. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. 1998;83(1):40–6.PubMed Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, Latrofa F, Mammoli C, Lippi F, Ceccarelli C, et al. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. 1998;83(1):40–6.PubMed
21.
go back to reference Walter MA, Christ-Crain M, Eckard B, Schindler C, Nitzsche EU, Muller-Brand J, Muller B. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Eur J Clin Investig. 2004;34(5):365–70. Walter MA, Christ-Crain M, Eckard B, Schindler C, Nitzsche EU, Muller-Brand J, Muller B. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Eur J Clin Investig. 2004;34(5):365–70.
22.
go back to reference Nakajo M, Tsuchimochi S, Tanabe H, Nakabeppu Y, Jinguji M. Three basic patterns of changes in serum thyroid hormone levels in Graves' disease during the one-year period after radioiodine therapy. Ann Nucl Med. 2005;19(4):297–308.PubMed Nakajo M, Tsuchimochi S, Tanabe H, Nakabeppu Y, Jinguji M. Three basic patterns of changes in serum thyroid hormone levels in Graves' disease during the one-year period after radioiodine therapy. Ann Nucl Med. 2005;19(4):297–308.PubMed
23.
go back to reference Enyi Ejeh MJ, Omotayo Ogunjobi K, Enyi Ejeh J, Solomon Adedapo K. J FE: effectiveness of fixed dose radioactive iodine (RAI) for the treatment of hyperthyroidism: experience of a teaching hospital in south West Nigeria. Mol Imaging Radionucl Ther. 2013;22(2):36–41.PubMedPubMedCentral Enyi Ejeh MJ, Omotayo Ogunjobi K, Enyi Ejeh J, Solomon Adedapo K. J FE: effectiveness of fixed dose radioactive iodine (RAI) for the treatment of hyperthyroidism: experience of a teaching hospital in south West Nigeria. Mol Imaging Radionucl Ther. 2013;22(2):36–41.PubMedPubMedCentral
24.
go back to reference Beslic N, Licina S, Sadija A, Milardovic R. Incidence of Hypothyreoidism after radioactive iodine-I131 treatment in Dependance of Hyperthyreoidism etiology and therapy dose. Med Arch. 2017;71(4):270–3.PubMedPubMedCentral Beslic N, Licina S, Sadija A, Milardovic R. Incidence of Hypothyreoidism after radioactive iodine-I131 treatment in Dependance of Hyperthyreoidism etiology and therapy dose. Med Arch. 2017;71(4):270–3.PubMedPubMedCentral
25.
go back to reference Tay WL, Chng CL, Tien CS, Loke KS, Lam WW, Fook-Chong SM, Tong AK. High thyroid stimulating receptor antibody titre and large goitre size at first-time radioactive iodine treatment are associated with treatment failure in Graves' disease. Ann Acad Med Singap. 2019;48(6):181–7.PubMed Tay WL, Chng CL, Tien CS, Loke KS, Lam WW, Fook-Chong SM, Tong AK. High thyroid stimulating receptor antibody titre and large goitre size at first-time radioactive iodine treatment are associated with treatment failure in Graves' disease. Ann Acad Med Singap. 2019;48(6):181–7.PubMed
26.
go back to reference Alevizaki CC, Alevizaki-Harhalaki MC, Ikkos DG. Radioiodine-131 treatment of thyrotoxicosis: dose required for and some factors affecting the early induction of hypothyroidism. Eur J Nucl Med. 1985;10(9–10):450–4.PubMed Alevizaki CC, Alevizaki-Harhalaki MC, Ikkos DG. Radioiodine-131 treatment of thyrotoxicosis: dose required for and some factors affecting the early induction of hypothyroidism. Eur J Nucl Med. 1985;10(9–10):450–4.PubMed
27.
go back to reference Boelaert K, Syed AA, Manji N, Sheppard MC, Holder RL, Gough SC, Franklyn JA. Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol. 2009;70(1):129–38. Boelaert K, Syed AA, Manji N, Sheppard MC, Holder RL, Gough SC, Franklyn JA. Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol. 2009;70(1):129–38.
28.
go back to reference Wan Mohamed WMI, Sayuti SC, Draman N. Hypothyroidism and its associated factors after radioactive iodine therapy among patients with hyperthyroidism in the northeast coast state of Malaysia. J Taibah Univ Med Sci. 2018;13(5):432–7.PubMedPubMedCentral Wan Mohamed WMI, Sayuti SC, Draman N. Hypothyroidism and its associated factors after radioactive iodine therapy among patients with hyperthyroidism in the northeast coast state of Malaysia. J Taibah Univ Med Sci. 2018;13(5):432–7.PubMedPubMedCentral
29.
go back to reference Yang D, Xue J, Ma W, Liu F, Fan Y, Rong J, Yang A, Yu Y. Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy. Nucl Med Commun. 2018;39(1):16–21.PubMed Yang D, Xue J, Ma W, Liu F, Fan Y, Rong J, Yang A, Yu Y. Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy. Nucl Med Commun. 2018;39(1):16–21.PubMed
30.
go back to reference Sapienza MT, Coura-Filho GB, Willegaignon J, Watanabe T, Duarte PS, Buchpiguel CA. Clinical and Dosimetric variables related to outcome after treatment of Graves' disease with 550 and 1110 MBq of 131I: results of a prospective randomized trial. Clin Nucl Med. 2015;40(9):715–9.PubMed Sapienza MT, Coura-Filho GB, Willegaignon J, Watanabe T, Duarte PS, Buchpiguel CA. Clinical and Dosimetric variables related to outcome after treatment of Graves' disease with 550 and 1110 MBq of 131I: results of a prospective randomized trial. Clin Nucl Med. 2015;40(9):715–9.PubMed
31.
go back to reference Sfiligoj D, Gaberscek S, Mekjavic PJ, Pirnat E, Zaletel K. Factors influencing the success of radioiodine therapy in patients with Graves' disease. Nucl Med Commun. 2015;36(6):560–5.PubMed Sfiligoj D, Gaberscek S, Mekjavic PJ, Pirnat E, Zaletel K. Factors influencing the success of radioiodine therapy in patients with Graves' disease. Nucl Med Commun. 2015;36(6):560–5.PubMed
Metadata
Title
Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves’ disease patients
Authors
Rui-Ting Hu
De-Shan Liu
Bin Li
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2020
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-020-00557-w

Other articles of this Issue 1/2020

BMC Endocrine Disorders 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.